Cargando…

KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2

PURPOSE: To describe the detailed retinal phenotype of KCNV2-associated retinopathy. STUDY DESIGN: Multicenter international retrospective case series. METHODS: Review of retinal imaging including fundus autofluorescence (FAF) and optical coherence tomography (OCT), including qualitative and quantit...

Descripción completa

Detalles Bibliográficos
Autores principales: Georgiou, Michalis, Fujinami, Kaoru, Vincent, Ajoy, Nasser, Fadi, Khateb, Samer, Vargas, Mauricio E., Thiadens, Alberta A.H.J., de Carvalho, Emanuel R., Nguyen, Xuan-Thanh-An, De Guimarães, Thales Antônio Cabral, Robson, Anthony G., Mahroo, Omar A., Pontikos, Nikolas, Arno, Gavin, Fujinami-Yokokawa, Yu, Leo, Shaun Michael, Liu, Xiao, Tsunoda, Kazushige, Hayashi, Takaaki, Jimenez-Rolando, Belen, Martin-Merida, Maria Inmaculada, Avila-Fernandez, Almudena, Carreño, Ester, Garcia-Sandoval, Blanca, Ayuso, Carmen, Sharon, Dror, Kohl, Susanne, Huckfeldt, Rachel M., Boon, Camiel J.F., Banin, Eyal, Pennesi, Mark E., Wissinger, Bernd, Webster, Andrew R., Héon, Elise, Khan, Arif O., Zrenner, Eberhart, Michaelides, Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710866/
https://www.ncbi.nlm.nih.gov/pubmed/33737031
http://dx.doi.org/10.1016/j.ajo.2021.03.004
_version_ 1784623256793251840
author Georgiou, Michalis
Fujinami, Kaoru
Vincent, Ajoy
Nasser, Fadi
Khateb, Samer
Vargas, Mauricio E.
Thiadens, Alberta A.H.J.
de Carvalho, Emanuel R.
Nguyen, Xuan-Thanh-An
De Guimarães, Thales Antônio Cabral
Robson, Anthony G.
Mahroo, Omar A.
Pontikos, Nikolas
Arno, Gavin
Fujinami-Yokokawa, Yu
Leo, Shaun Michael
Liu, Xiao
Tsunoda, Kazushige
Hayashi, Takaaki
Jimenez-Rolando, Belen
Martin-Merida, Maria Inmaculada
Avila-Fernandez, Almudena
Carreño, Ester
Garcia-Sandoval, Blanca
Ayuso, Carmen
Sharon, Dror
Kohl, Susanne
Huckfeldt, Rachel M.
Boon, Camiel J.F.
Banin, Eyal
Pennesi, Mark E.
Wissinger, Bernd
Webster, Andrew R.
Héon, Elise
Khan, Arif O.
Zrenner, Eberhart
Michaelides, Michel
author_facet Georgiou, Michalis
Fujinami, Kaoru
Vincent, Ajoy
Nasser, Fadi
Khateb, Samer
Vargas, Mauricio E.
Thiadens, Alberta A.H.J.
de Carvalho, Emanuel R.
Nguyen, Xuan-Thanh-An
De Guimarães, Thales Antônio Cabral
Robson, Anthony G.
Mahroo, Omar A.
Pontikos, Nikolas
Arno, Gavin
Fujinami-Yokokawa, Yu
Leo, Shaun Michael
Liu, Xiao
Tsunoda, Kazushige
Hayashi, Takaaki
Jimenez-Rolando, Belen
Martin-Merida, Maria Inmaculada
Avila-Fernandez, Almudena
Carreño, Ester
Garcia-Sandoval, Blanca
Ayuso, Carmen
Sharon, Dror
Kohl, Susanne
Huckfeldt, Rachel M.
Boon, Camiel J.F.
Banin, Eyal
Pennesi, Mark E.
Wissinger, Bernd
Webster, Andrew R.
Héon, Elise
Khan, Arif O.
Zrenner, Eberhart
Michaelides, Michel
author_sort Georgiou, Michalis
collection PubMed
description PURPOSE: To describe the detailed retinal phenotype of KCNV2-associated retinopathy. STUDY DESIGN: Multicenter international retrospective case series. METHODS: Review of retinal imaging including fundus autofluorescence (FAF) and optical coherence tomography (OCT), including qualitative and quantitative analyses. RESULTS: Three distinct macular FAF features were identified: (1) centrally increased signal (n = 35, 41.7%), (2) decreased autofluorescence (n = 27, 31.1%), and (3) ring of increased signal (n = 37, 44.0%). Five distinct FAF groups were identified based on combinations of those features, with 23.5% of patients changing the FAF group over a mean (range) follow-up of 5.9 years (1.9-13.1 years). Qualitative assessment was performed by grading OCT into 5 grades: (1) continuous ellipsoid zone (EZ) (20.5%); (2) EZ disruption (26.1%); (3) EZ absence, without optical gap and with preserved retinal pigment epithelium complex (21.6%); (4) loss of EZ and a hyporeflective zone at the foveola (6.8%); and (5) outer retina and retinal pigment epithelium complex loss (25.0%). Eighty-six patients had scans available from both eyes, with 83 (96.5%) having the same grade in both eyes, and 36.1% changed OCT grade over a mean follow-up of 5.5 years. The annual rate of outer nuclear layer thickness change was similar for right and left eyes. CONCLUSIONS: KCNV2-associated retinopathy is a slowly progressive disease with early retinal changes, which are predominantly symmetric between eyes. The identification of a single OCT or FAF measurement as an endpoint to determine progression that applies to all patients may be challenging, although outer nuclear layer thickness is a potential biomarker. Findings suggest a potential window for intervention until 40 years of age.
format Online
Article
Text
id pubmed-8710866
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Science
record_format MEDLINE/PubMed
spelling pubmed-87108662021-12-30 KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2 Georgiou, Michalis Fujinami, Kaoru Vincent, Ajoy Nasser, Fadi Khateb, Samer Vargas, Mauricio E. Thiadens, Alberta A.H.J. de Carvalho, Emanuel R. Nguyen, Xuan-Thanh-An De Guimarães, Thales Antônio Cabral Robson, Anthony G. Mahroo, Omar A. Pontikos, Nikolas Arno, Gavin Fujinami-Yokokawa, Yu Leo, Shaun Michael Liu, Xiao Tsunoda, Kazushige Hayashi, Takaaki Jimenez-Rolando, Belen Martin-Merida, Maria Inmaculada Avila-Fernandez, Almudena Carreño, Ester Garcia-Sandoval, Blanca Ayuso, Carmen Sharon, Dror Kohl, Susanne Huckfeldt, Rachel M. Boon, Camiel J.F. Banin, Eyal Pennesi, Mark E. Wissinger, Bernd Webster, Andrew R. Héon, Elise Khan, Arif O. Zrenner, Eberhart Michaelides, Michel Am J Ophthalmol Original Article PURPOSE: To describe the detailed retinal phenotype of KCNV2-associated retinopathy. STUDY DESIGN: Multicenter international retrospective case series. METHODS: Review of retinal imaging including fundus autofluorescence (FAF) and optical coherence tomography (OCT), including qualitative and quantitative analyses. RESULTS: Three distinct macular FAF features were identified: (1) centrally increased signal (n = 35, 41.7%), (2) decreased autofluorescence (n = 27, 31.1%), and (3) ring of increased signal (n = 37, 44.0%). Five distinct FAF groups were identified based on combinations of those features, with 23.5% of patients changing the FAF group over a mean (range) follow-up of 5.9 years (1.9-13.1 years). Qualitative assessment was performed by grading OCT into 5 grades: (1) continuous ellipsoid zone (EZ) (20.5%); (2) EZ disruption (26.1%); (3) EZ absence, without optical gap and with preserved retinal pigment epithelium complex (21.6%); (4) loss of EZ and a hyporeflective zone at the foveola (6.8%); and (5) outer retina and retinal pigment epithelium complex loss (25.0%). Eighty-six patients had scans available from both eyes, with 83 (96.5%) having the same grade in both eyes, and 36.1% changed OCT grade over a mean follow-up of 5.5 years. The annual rate of outer nuclear layer thickness change was similar for right and left eyes. CONCLUSIONS: KCNV2-associated retinopathy is a slowly progressive disease with early retinal changes, which are predominantly symmetric between eyes. The identification of a single OCT or FAF measurement as an endpoint to determine progression that applies to all patients may be challenging, although outer nuclear layer thickness is a potential biomarker. Findings suggest a potential window for intervention until 40 years of age. Elsevier Science 2021-10 /pmc/articles/PMC8710866/ /pubmed/33737031 http://dx.doi.org/10.1016/j.ajo.2021.03.004 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Article
Georgiou, Michalis
Fujinami, Kaoru
Vincent, Ajoy
Nasser, Fadi
Khateb, Samer
Vargas, Mauricio E.
Thiadens, Alberta A.H.J.
de Carvalho, Emanuel R.
Nguyen, Xuan-Thanh-An
De Guimarães, Thales Antônio Cabral
Robson, Anthony G.
Mahroo, Omar A.
Pontikos, Nikolas
Arno, Gavin
Fujinami-Yokokawa, Yu
Leo, Shaun Michael
Liu, Xiao
Tsunoda, Kazushige
Hayashi, Takaaki
Jimenez-Rolando, Belen
Martin-Merida, Maria Inmaculada
Avila-Fernandez, Almudena
Carreño, Ester
Garcia-Sandoval, Blanca
Ayuso, Carmen
Sharon, Dror
Kohl, Susanne
Huckfeldt, Rachel M.
Boon, Camiel J.F.
Banin, Eyal
Pennesi, Mark E.
Wissinger, Bernd
Webster, Andrew R.
Héon, Elise
Khan, Arif O.
Zrenner, Eberhart
Michaelides, Michel
KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2
title KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2
title_full KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2
title_fullStr KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2
title_full_unstemmed KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2
title_short KCNV2-Associated Retinopathy: Detailed Retinal Phenotype and Structural Endpoints—KCNV2 Study Group Report 2
title_sort kcnv2-associated retinopathy: detailed retinal phenotype and structural endpoints—kcnv2 study group report 2
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8710866/
https://www.ncbi.nlm.nih.gov/pubmed/33737031
http://dx.doi.org/10.1016/j.ajo.2021.03.004
work_keys_str_mv AT georgioumichalis kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT fujinamikaoru kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT vincentajoy kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT nasserfadi kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT khatebsamer kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT vargasmauricioe kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT thiadensalbertaahj kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT decarvalhoemanuelr kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT nguyenxuanthanhan kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT deguimaraesthalesantoniocabral kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT robsonanthonyg kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT mahrooomara kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT pontikosnikolas kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT arnogavin kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT fujinamiyokokawayu kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT leoshaunmichael kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT liuxiao kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT tsunodakazushige kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT hayashitakaaki kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT jimenezrolandobelen kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT martinmeridamariainmaculada kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT avilafernandezalmudena kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT carrenoester kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT garciasandovalblanca kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT ayusocarmen kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT sharondror kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT kohlsusanne kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT huckfeldtrachelm kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT booncamieljf kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT banineyal kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT pennesimarke kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT wissingerbernd kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT websterandrewr kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT heonelise kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT khanarifo kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT zrennereberhart kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2
AT michaelidesmichel kcnv2associatedretinopathydetailedretinalphenotypeandstructuralendpointskcnv2studygroupreport2